Condition
Vibrio Infections
Total Trials
6
Recruiting
0
Active
0
Completed
4
Success Rate
80.0%-7% vs avg
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
80.0%
-6.5% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results80% success
Data Visualizations
Phase Distribution
5Total
P 2 (4)
P 3 (1)
Trial Status
Completed4
Unknown1
Terminated1
Trial Success Rate
80.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT04451707CompletedPrimary
Epidemiology Non-cholera Vibrio Infections
NCT00548054Phase 2Unknown
Safety and Immunogenicity of a Killed Oral Cholera Vaccine in Infants
NCT00289224Phase 3Completed
Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata
NCT00624975Phase 2Terminated
Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants
NCT00741637Phase 2Completed
Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults
NCT00419133Phase 2Completed
Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine
Showing all 6 trials